초록

The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other disease states associated with enzymes in the coagulation pathway.

대표청구항 ▼

1. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectivel

1. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1 sec?1×103.2. The elastase-resistant ATIII of claim 1, wherein the ATIII further comprises three additional modifications, wherein the modifications occur at positions P6, P7, and P8 of the ATIII, wherein P6, P7, and P8 are the sixth, seventh, and eighth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P8 is glutamic acid, wherein residue P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, and wherein P6 comprises an amino acid selected from the group consisting of: leucine; glycine; glutamic acid; and threonine.3. The elastase-resistant ATIII of claim 1, wherein the ATIII further comprises one additional modification, wherein the modification occurs at position P3 of the ATIII, wherein P3 is the third amino acid towards the amino terminal side of the scissile bond of the reactive center, and wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine.4. The ATIII of claim 1, wherein the ATIII is in a pharmaceutically acceptable formulation.5. The elastase-resistant ATIII of claim 1, wherein the ATIII has enhanced heparin binding activity.6. The ATIII of claim 5, wherein the ATIII is in a pharmaceutically acceptable formulation.7. The elastase-resistant ATIII of claim 1, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.8. The ATIII of claim 7, wherein the ATIII is in a pharmaceutically acceptable formulation.9. The ATIII of claim 7, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.10. The ATIII of claim 7, wherein the glycosylation site occurs at position 192 of SEQ ID NO:35.11. The ATIII of claim 1, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.12. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine, glycine, glutamic acid, and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.13. The elastase-resistant ATIII of claim 12, wherein P6 is glycine.14. The elastase-resistant ATIII of claim 13, wherein P5 is phenylalanine or glutamic acid.15. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P3 and P6 of the ATIII, wherein P3 and P6 are the third and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.16. The elastase-resistant ATIII of claim 15, wherein P3 is serine.17. The elastase-resistant ATIII of claim 15, wherein P6 is glycine.18. The elastase-resistant AIII of claim 17, wherein P3 is serine.19. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P3, P6, and P7 of the ATIII, wherein P3, P6, and P7 are the third, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, and wherein P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.20. The elastase-resistant ATIII of claim 19, wherein P7 is glutamic acid.21. The elastase-resistant ATIII of claim 20, wherein P3 is serine, and wherein P6 is glycine.22. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is phenylalanine, wherein P5 is phenylalanine, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the resistant-resistant ATIII has greater resistance to human neutrophil lactase as compared to plasma ATIII wherein the ATIII retains an antithrombin activity defined by a kapp of at least about 0.2M?1S?1×103.23. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is alanine, wherein P5 is glutamic acid, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.24. An elastase-resistant antithrombin III wherein the amino acid sequence of residues 387-391 according to SEQ ID NO:35 is substituted with the amino acid sequence of residues 3 through 7 of SEQ ID NO:4, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII.25. An resistant-resistant antithrombin III wherein the amino acid sequence of residues 387-391 according to SEQ ID NO:35 is substituted with the amino acid sequence of residues 3 through 7 of SEQ ID NO:5, wherein the resistant-resistant ATIII has greater resistance to human neutrophil lactase as compared to plasma ATIII.26. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.27. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?S?1×103.28. An elastase-resistant antithrombin III (ATIII) comprising at least four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.29. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P6 of the ATIII, wherein P4 and P6 are the fourth and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the resistant-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.30. The ATIII of claim 29, wherein the P4 is alanine and P6 is leucine.31. The elastase-resistant ATIII of claim 30, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.32. The ATIII of claim 31, wherein the ATIII is in a pharmaceutically acceptable formulation.33. The ATIII of claim 31, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.34. The ATIII of claim 31, wherein the glycosylation site occurs at position 192 of SEQ ID NO:35.35. The ATIII of claim 29, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.36. An elastase-resistant antithrombin III (ATIII) comprising four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.37. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.38. The elastase-resistant ATIII of claim 37, wherein the ATIII further comprises three additional modifications, wherein the modifications occur at positions P6, P7, and P8 of the ATIII, wherein P6, P7, and P8 are the sixth, seventh, and eighth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P8 is glutamic acid, wherein residue P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, and wherein P6 comprises an amino acid selected from the group consisting of: leucine; glycine; glutamic acid; and threonine.39. The elastase-resistant ATIII of claim 37 wherein the ATIII further comprises one additional modification, wherein the modification occurs at position P3 of the ATIII, wherein P3 is the third amino acid towards the amino terminal side of the scissile bond of the reactive center, and wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine.40. The ATIII of claim 37, wherein the ATIII is in a pharmaceutically acceptable formulation.41. The elastase-resistant ATIII of claim 37, wherein the ATIII has enhanced heparin binding activity.42. The ATIII of claim 41, wherein the ATIII is in a pharmaceutically acceptable formulation.43. The elastase-resistant ATIII of claim 37, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.44. The ATIII of claim 43, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.45. The ATIII of claim 43, wherein the glycosylation site occurs at position 192 of SEQ ID NO:35.46. The ATIII of claim 37, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.47. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine, glycine, glutamic acid, and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1103.48. The elastase-resistant ATIII of claim 47, wherein P6 is glycine.49. The elastase-resistant ATIII of claim 48, wherein P5 is phenylalanine or glutamic acid.50. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P3 and P6 of the ATIII, wherein P3 and P6 are the third and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.51. The elastase-resistant ATIII of claim 50, wherein P3 is serine.52. The elastase-resistant ATIII of claim 50, wherein P6 is glycine.53. The elastase-resistant ATIII of claim 52, wherein P3 is serine.54. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P3, P6, and P7 of the ATIII, wherein P3, P6, and P7 are the third, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, and wherein P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.55. The elastase-resistant ATIII of claim 54, wherein P7 is glutamic acid.56. The elastase-resistant ATIII of claim 55, wherein P3 is serine, and wherein P6 is glycine.57. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is phenylalanine, wherein P5is phenylalanine, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103?.58. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is alanine, wherein P5 is glutamic acid, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.59. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.60. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.61. An elastase-resistant antithrombin III (ATIII) comprising at least four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.62. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P6 of the ATIII, wherein P4 and P6 are the fourth and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.63. The ATIII of claim 62, wherein the P4 is alanine and P6 is leucine.64. The elastase-resistant ATIII of claim 63, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.65. The ATIII of claim 64, wherein the ATIII is in a pharmaceutically acceptable formulation.66. The ATIII of claim 64, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.67. The ATIII of claim 64, wherein the glycosylation site occurs at position 155 of SEQ ID NO:35.68. The ATIII of claim 62, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.69. An elastase-resistant antithrombin III (ATIII) comprising four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity defined by a kapp of at least about 0.2M?1S?1×103.70. An elastase-resistant antithrombin m (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.71. The ATIII of claim 70, wherein the ATIII is in a pharmaceutically acceptable formulation.72. The elastase-resistant ATIII of claim 70 wherein the ATIII further comprises three additional modifications, wherein the modifications occur at positions P6, P7, and P8 of the ATIII, wherein P6, P7, and P8 are the sixth, seventh, and eighth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P8 is glutamic acid, wherein residue P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, and wherein P6 comprises an amino acid selected from the group consisting of: leucine; glycine; glutamic acid; and threonine.73. The elastase-resistant ATIII of claim 70, wherein the ATIII further comprises one additional modification, wherein the modification occurs at position P3 of the ATIII, wherein P3 is the third amino acid towards the amino terminal side of the scissile bond of the reactive center, and wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine.74. The ATIII of claim 70, wherein the ATIII is in a pharmaceutically acceptable formulation.75. The elastase-resistant ATIII of claim 70, wherein the ATIII has enhanced heparin binding activity.76. The ATIII of claim 75, wherein the AIII is in a pharmaceutically acceptable formulation.77. The elastase-resistant ATIII of claim 70, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.78. The ATIII of claim 77, wherein the ATIII is in a pharmaceutically acceptable formulation.79. The ATIII of claim 77, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.80. The ATIII of claim 77, wherein the glycosylation site occurs at position 192 of SEQ ID NO:35.81. The ATIII of claim 70, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.82. An elastase-resistant antithrombin III (ATIII) comprising four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.83. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine, glycine, glutamic acid, and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.84. The elastase-resistant ATIII of claim 83, wherein P6 is glycine.85. The elastase-resistant ATIII of claim 84, wherein P5 is phenylalanine or glutamic acid.86. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P3 and P6 of the ATIII, wherein P3 and P6 are the third and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.87. The elastase-resistant ATIII of claim 86, wherein P3 is serine.88. The elastase-resistant ATIII of claim 86, wherein P6 is glycine.89. The elastase-resistant ATIII of claim 88, wherein P3 is serine.90. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P3, P6, and P7 of the ATIII, wherein P3, P6, and P7 are the third, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, and wherein P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, wherein the resistant-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.91. The elastase-resistant ATIII of claim 90, wherein P7 is glutamic acid.92. The elastase-resistant ATIII of claim 91, wherein P3 is serine, and wherein P6 is glycine.93. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is phenylalanine, wherein P5 is phenylalanine, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.94. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is alanine, wherein P5 is glutamic acid, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.95. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.96. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.97. An elastase-resistant antithrombin III (ATIII) comprising at least four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 is alanine, wherein P5is glutamic acid; and wherein P6 is leucine, wherein the resistant-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.98. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P6 of the ATIII, wherein P4 and P6 are the fourth and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a thrombin inhibitory activity which is at least about two percent of plasma ATIII thrombin inhibitory activity.99. The ATIII of claim 98, wherein the P4 is alamine and P6 is leucine.100. The elastase-resistant ATIII of claim 99, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.101. The ATIII of claim 100, wherein the ATIII is in a pharmaceutically acceptable formulation.102. The ATIII of claim 100, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.103. The ATIII of claim 100, wherein the glycosylation site occurs at position 155 of SEQ ID NO:35.104. The ATIII of claim 98, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.105. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.106. The elastase-resistant ATIII of claim 105 wherein the ATIII further comprises three additional modifications, wherein the modifications occur at positions P6, P7, and P8 of the ATIII, wherein P6, P7, and P8 are the sixth, seventh, and eighth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P8 is glutamic acid, wherein residue P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, and wherein P6 comprises an amino acid selected from the group consisting of: leucine; glycine; glutamic acid; and threonine.107. The elastase-resistant ATIII of claim 105 wherein the ATIII further comprises one additional modification, wherein the modification occurs at position P3 of the ATIII, wherein P3 is the third amino acid towards the amino terminal side of the scissile bond of the reactive center, and wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine.108. The ATIII of claim 105, wherein the ATIII is in a pharmaceutically acceptable formulation.109. The elastase-resistant ATIII of claim 105, wherein the ATIII has enhanced heparin binding activity.110. The ATIII of claim 109, wherein the ATIII is in a pharmaceutically acceptable formulation.111. The elastase-resistant ATIII of claim 105, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.112. The ATIII of claim 111, wherein the ATIII is in a pharmaceutically acceptable formulation.113. The ATIII of claim 111, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.114. The ATIII of claim 111, wherein the glycosylation site occurs at position 192 of SEQ ID NO:35.115. The ATIII of claim 105, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.116. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine, glycine, glutamic acid, and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.117. The elastase-resistant ATIII of claim 116, wherein P6 is glycine.118. The elastase-resistant ATIII of claim 117, wherein P5 is phenylalanine or glutamic acid.119. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P3 and P6 of the ATIII, wherein P3 and P6 are the third and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.120. The elastase-resistant ATIII of claim 119, wherein P3 is serine.121. The elastase-resistant ATIII of claim 120, wherein P6 is glycine.122. The elastase-resistant ATIII of claim 121, wherein P3 is serine.123. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P3, P6, and P7 of the ATIII, wherein P3, P6, and P7 are the third, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 comprises an amino acid selected from the group consisting of isoleucine; serine; glycine; and asparagine, wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, and wherein P7 comprises an amino acid selected from the group consisting of glutamic acid and glutamine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.124. The elastase-resistant ATIII of claim 123, wherein P7 is glutamic acid.125. The elastase-resistant ATIII of claim 124, wherein P3 is serine, and wherein P6 is glycine.126. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is phenylalanine, wherein P5 is phenylalanine, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the resistant-resistant ATIII has greater resistance to human neutrophil lactase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.127. An elastase-resistant antithrombin III (ATIII) comprising at least five amino acid modifications, wherein the modifications occur at positions P3, P4, P5, P6, and P7 of the ATIII, wherein P3, P4, P5, P6, and P7 are the third, fourth, fifth, sixth, and seventh amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is serine, wherein P4 is alanine, wherein P5 is glutamic acid, wherein P6 is glycine, and wherein P7 is glutamic acid, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.128. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P5 of the ATIII, wherein P4 and P5 are the fourth and fifth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; glycine; and proline, and wherein P5 comprises an amino acid selected from the group consisting of glutamic acid; glycine; and proline, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.129. An elastase-resistant antithrombin III (ATIII) comprising at least three modifications, wherein the modifications occur at positions P4, P5, and P6 of the ATIII, wherein P4, P5, and P6 are the fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.130. An elastase-resistant antithrombin III (ATIII) comprising at least four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 is alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.131. An elastase-resistant antithrombin III (ATIII) comprising four modifications, wherein the modifications occur at positions P3, P4, P5, and P6 of the ATIII, wherein P3, P4, P5, and P6 are the third, fourth, fifth, and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P3 is isoleucine, wherein P4 alanine, wherein P5 is glutamic acid; and wherein P6 is leucine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.132. An elastase-resistant antithrombin III (ATIII) comprising at least two modifications, wherein the modifications occur at positions P4 and P6 of the ATIII, wherein P4 and P6 are the fourth and sixth amino acids towards the amino terminal side of the scissile bond of the reactive center respectively, wherein P4 comprises an amino acid selected from the group consisting of alanine; phenylalanine; glycine; and proline, and wherein P6 comprises an amino acid selected from the group consisting of leucine; glycine; glutamic acid; and threonine, wherein the elastase-resistant ATIII has greater resistance to human neutrophil elastase as compared to plasma ATIII wherein the ATIII retains a factor Xa inhibitory activity which is at least about 12.5 percent of plasma ATIII factor Xa inhibitory activity.133. The ATIII of claim 132, wherein the P4 is alanine and P6 is leucine.134. The elastase-resistant ATIII of claim 133, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation two residues subsequent to a glycosylation site.135. The ATIII of claim 134, wherein the ATIII is in a pharmaceutically acceptable formulation.136. The ATIII of claim 134, wherein the glycosylation site occurs at position 135 of SEQ ID NO:35.137. The ATIII of claim 134, wherein the glycosylation site occurs at position 155 of SEQ ID NO:35.138. The ATIII of claim 132, wherein the ATIII has enhanced heparin binding activity, and wherein the ATIII has a mutation at position 96, 135, 155, or 192 of SEQ ID NO:35.